Drug comparisons
Erenumab vs Galcanezumab
Compare Erenumab (Aimovig) and Galcanezumab (Emgality) for migraine prevention. Erenumab targets the CGRP receptor while Galcanezumab binds the ligand. Both monoclonal antibodies show similar efficacy and dosing but vary in side effects and patient response. Learn key differences to choose the best option.
No comparison dimensions are available for this page.
Clinical context
Patients with episodic or chronic migraine seeking CGRP monoclonal antibody prevention often compare Erenumab and Galcanezumab.
Bottom line
Both Erenumab and Galcanezumab are effective CGRP inhibitors for migraine prevention, with the better option depending on individual patient factors.
All medication comparisons